Carisma Therapeutics, Inc.
CARMOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$4185
P/E Ratio—
52W High$1.27
52W Low$0.0001
Carisma Therapeutics, Inc. (CARM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CARM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $19.63M | $14.92M | $9.83M | $26.54M | $11.24M |
| Cost of Revenue | $59.67M | $74.13M | $0.00M | $0.09M | $0.00M |
| Gross Profit | ($40.04M) | ($59.21M) | $9.83M | $26.46M | $11.24M |
| Gross Margin %(computed) | -203.96% | -396.85% | 100.00% | 99.68% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $59.67M | $74.13M | $56.62M | $25.23M | $23.29M |
| G&A Expenses | $20.14M | $29.52M | $9.38M | $0.00M | $5.09M |
| Total Operating Expenses | $22.14M | $29.52M | $66.00M | $54.62M | $28.38M |
| Operating Income | ($62.18M) | ($88.73M) | ($56.16M) | ($28.16M) | ($28.38M) |
| Operating Margin %(computed) | -316.72% | -594.75% | -571.10% | -106.09% | -252.56% |
| Interest Income | $1.70M | $1.94M | $0.00M | $0.01M | $0.03M |
| Interest Expense | $0.00M | $0.00M | $3.15M | $0.00M | $0.00M |
| Income Before Tax | ($60.48M) | ($86.88M) | ($61.23M) | ($8.61M) | ($28.35M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | ($8.27M) | $0.00M |
| Net Income | ($60.48M) | ($86.88M) | ($61.23M) | ($0.34M) | ($28.35M) |
| Net Margin %(computed) | -308.05% | -582.34% | -622.60% | -1.27% | -252.31% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.46 | $-2.59 | $-1.52 | $-0.04 | $-3.81 |
| Wtd Avg Shares | 41.46M | 33.52M | 40.26M | 9.12M | 5.91M |
| EBITDA | ($56.83M) | ($85.89M) | ($56.19M) | ($8.52M) | ($27.93M) |
| EBITDA Margin %(computed) | -289.45% | -575.74% | -571.36% | -32.11% | -248.58% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Carisma Therapeutics, Inc. data
About Carisma Therapeutics, Inc. (CARM) Income Statement
Carisma Therapeutics, Inc. (CARM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CARM reported revenue of $0.02B, gross profit of ($0.04B) (gross margin -203.96%), and net income of ($0.06B) — a net profit margin of -308.05%.
Frequently asked questions
CARM · 4 questionsCarisma Therapeutics, Inc. (CARM) reported revenue of $0.02B for 2024, up 31.6% year-over-year.
CARM revenueCARM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09